146 related articles for article (PubMed ID: 34756686)
1. Quality of Life in an e-Cohort of Women Treated by Endocrine Therapy for Early Breast Cancer.
Benoit L; Cambra C; Rouzier R; Cottu P; Rodrigues M; Reyal F; Research Network S; Bonneau C
Clin Breast Cancer; 2022 Apr; 22(3):e352-e361. PubMed ID: 34756686
[TBL] [Abstract][Full Text] [Related]
2. Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy.
Akin Telli T; Ozturk MA; Alan O; Hasanov R; Kostek O; Arikan R; Basoglu T; Kaya S; Ercelep O; Akgul Babacan N; Dane F; Yumuk PF
Future Oncol; 2022 Jul; 18(22):2425-2439. PubMed ID: 35695547
[TBL] [Abstract][Full Text] [Related]
3. Quality of life in elderly breast cancer patients with localized disease receiving endocrine treatment: a prospective study.
Arraras JI; Illarramendi JJ; Manterola A; Asin G; Salgado E; Arrondo P; Dominguez MA; Arrazubi V; Martinez E; Viudez A; de la Cruz S; Vera R
Clin Transl Oncol; 2019 Sep; 21(9):1231-1239. PubMed ID: 30712234
[TBL] [Abstract][Full Text] [Related]
4. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
Ferreira AR; Di Meglio A; Pistilli B; Gbenou AS; El-Mouhebb M; Dauchy S; Charles C; Joly F; Everhard S; Lambertini M; Coutant C; Cottu P; Lerebours F; Petit T; Dalenc F; Rouanet P; Arnaud A; Martin A; Berille J; Ganz PA; Partridge AH; Delaloge S; Michiels S; Andre F; Vaz-Luis I
Ann Oncol; 2019 Nov; 30(11):1784-1795. PubMed ID: 31591636
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in Spanish postmenopausal breast cancer patients with localized disease who finish endocrine treatment: a prospective study.
Arraras JI; Illarramendi JJ; Manterola A; de la Cruz S; Zarandona U; Ibañez B; Salgado E; Visus I; Barrado M; Teiejira L; Martinez MI; Martinez E; Vera R
Menopause; 2023 Jun; 30(6):613-620. PubMed ID: 37022296
[TBL] [Abstract][Full Text] [Related]
6. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Kahan Z; Gil-Gil M; Ruiz-Borrego M; Carrasco E; Ciruelos E; Muñoz M; Bermejo B; Margeli M; Antón A; Casas M; Csöszi T; Murillo L; Morales S; Calvo L; Lang I; Alba E; de la Haba-Rodriguez J; Ramos M; López IÁ; Gal-Yam E; Garcia-Palomo A; Alvarez E; González-Santiago S; Rodríguez CA; Servitja S; Corsaro M; Rodrigálvarez G; Zielinski C; Martín M
Eur J Cancer; 2021 Oct; 156():70-82. PubMed ID: 34425406
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
Fallowfield LJ; Bliss JM; Porter LS; Price MH; Snowdon CF; Jones SE; Coombes RC; Hall E
J Clin Oncol; 2006 Feb; 24(6):910-7. PubMed ID: 16484701
[TBL] [Abstract][Full Text] [Related]
9. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
10. Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.
Freites-Martinez A; Shapiro J; Chan D; Fornier M; Modi S; Gajria D; Dusza S; Goldfarb S; Lacouture ME
JAMA Dermatol; 2018 Jun; 154(6):670-675. PubMed ID: 29641806
[TBL] [Abstract][Full Text] [Related]
11. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
Hamood R; Hamood H; Merhasin I; Keinan-Boker L
Osteoporos Int; 2019 Jan; 30(1):187-200. PubMed ID: 30413856
[TBL] [Abstract][Full Text] [Related]
12. Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
Ferreira AR; Palha A; Correia L; Filipe P; Rodrigues V; Miranda A; André R; Fernandes J; Gouveia J; Passos-Coelho JL; Moreira A; Brito M; Ribeiro J; Metzger-Filho O; Lin NU; Costa L; Vaz-Luis I
Breast; 2018 Feb; 37():107-113. PubMed ID: 29131988
[TBL] [Abstract][Full Text] [Related]
13. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
[TBL] [Abstract][Full Text] [Related]
14. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
[TBL] [Abstract][Full Text] [Related]
15. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
16. Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters.
Borreani C; Alfieri S; Infante G; Miceli R; Mariani P; Bosisio M; Vernieri C; Bianchi GV; Capri G
Oncology; 2021; 99(2):84-95. PubMed ID: 32992318
[TBL] [Abstract][Full Text] [Related]
17. Adherence and quality of life in women with breast cancer being treated with oral hormone therapy.
Stahlschmidt R; Ferracini AC; de Souza CM; de Medeiros LM; Juliato CRT; Mazzola PG
Support Care Cancer; 2019 Oct; 27(10):3799-3804. PubMed ID: 30729297
[TBL] [Abstract][Full Text] [Related]
18. Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study.
Laroche F; Perrot S; Medkour T; Cottu PH; Pierga JY; Lotz JP; Beerblock K; Tournigand C; Chauvenet L; Bouhassira D; Coste J
PLoS One; 2017; 12(11):e0187165. PubMed ID: 29117210
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study.
Sund M; Garcia-Argibay M; Garmo H; Ahlgren J; Wennstig AK; Fredriksson I; Lindman H; Valachis A
Breast; 2021 Oct; 59():157-164. PubMed ID: 34265496
[TBL] [Abstract][Full Text] [Related]
20. Adherence to endocrine therapy including ovarian suppression: A large observational cohort study of US women with early breast cancer.
Reeder-Hayes KE; Mayer SE; Lund JL
Cancer; 2021 Apr; 127(8):1220-1227. PubMed ID: 33508140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
